A5025063745- Advanced battery technologies research
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Advanced Battery Materials and Technologies
- Supercapacitor Materials and Fabrication
- Liver physiology and pathology
- Hepatocellular Carcinoma Treatment and Prognosis
- Advancements in Battery Materials
- Blood Pressure and Hypertension Studies
- Peptidase Inhibition and Analysis
- Pharmacology and Obesity Treatment
- Cancer Genomics and Diagnostics
- Statistical Methods in Clinical Trials
- Reproductive System and Pregnancy
- Statistical Methods and Bayesian Inference
- Cancer-related molecular mechanisms research
- Chronic Kidney Disease and Diabetes
- Angiogenesis and VEGF in Cancer
- Neutropenia and Cancer Infections
- Lung Cancer Research Studies
- Cancer, Hypoxia, and Metabolism
- Respiratory Support and Mechanisms
- Histone Deacetylase Inhibitors Research
- Renal cell carcinoma treatment
- Mental Health and Patient Involvement
Merck (Germany)
2020-2024
Hubei Normal University
2023-2024
Gaozhou People's Hospital
2024
Yantai Laiyang Central Hospital
2018-2023
Zhengzhou People's Hospital
2019
Merck Serono (Switzerland)
2019
University of Pittsburgh
2011
Second Affiliated Hospital of Dalian Medical University
2008
Abstract Background This study was performed to determine the effects of human placenta mesenchymal stem cell (hPMSC) transplantation on granulosa apoptosis and anti-Müllerian hormone (AMH) follicle-stimulating receptor (FSHR) expression in autoimmune drug-induced premature ovarian failure (POF) mice. The aim this research is investigate mechanisms hPMSCs reserve capacity. Methods POF mice model established by injection zona pellucida 3 peptide (pZP3). hPMSC conducted intravenous into...
<h3>Background</h3> Antibodies targeting programmed death-1 (PD-1) or death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort JAVELIN Solid Tumor trial assessed efficacy and safety avelumab (anti–PD-L1) monotherapy patients with mRCC as either first-line (1 L) second-line (2 treatment. <h3>Methods</h3> Patients a clear-cell component who were naive L subgroup) had disease progression after one prior line therapy...
This open-label, Phase 1b/2 study evaluated the highly selective MET inhibitor tepotinib in systemic anticancer treatment (SACT)-naive Asian patients with advanced hepatocellular carcinoma (aHCC) overexpression.In 2b, was orally administered once daily (300, 500 or 1,000 mg) to adults aHCC. The primary endpoints were dose-limiting toxicities (DLTs) and adverse events (AEs). 2 randomised SACT-naive aHCC overexpression (recommended dose [RP2D]) sorafenib 400 mg twice daily. endpoint...
Background Recurrent and/or metastatic (R/M) disease develops in approximately 65% of patients with squamous cell carcinoma the head and neck (SCCHN) is associated a poor prognosis. Immune checkpoint inhibitors have proven effective multiple tumor types, including R/M SCCHN. We report efficacy safety avelumab (antiprogrammed death ligand 1 antibody) an expansion cohort platinum-refractory/ineligible SCCHN enrolled phase I JAVELIN Solid Tumor trial ( NCT01772004 ). Methods Eligible were aged...
Introduction Avelumab, an antiprogrammed death ligand-1 antibody, is approved as a monotherapy for treatment of metastatic Merkel cell carcinoma and advanced urothelial carcinoma, in combination with axitinib renal carcinoma. We report the efficacy safety first-line avelumab non-small lung cancer (NSCLC). Methods In phase I expansion cohort JAVELIN Solid Tumor trial, patients treatment-naive, metastatic, or recurrent NSCLC received 10 mg/kg intravenously every 2 weeks. Endpoints included...
Abstract Like other monoclonal antibodies, immune checkpoint inhibitors may be immunogenic in some patients, potentially affecting pharmacokinetics (PKs) and clinical outcomes. In post hoc analyses, we characterized antidrug antibody (ADA) development with avelumab monotherapy patients metastatic Merkel cell carcinoma (mMCC) from the JAVELIN 200 trial (first‐line [1L; N = 116] second‐line or later [≥2L; 88] cohorts) advanced urothelial (aUC) Bladder 100 (1L maintenance [ 350]) Solid Tumor...
J Clin Hypertens (Greenwich) . 2012; 14:588–592. © 2012 Wiley Periodicals, Inc. Blood pressure (BP) reductions when combining blockers of the renin‐angiotensin system (RAS) and β‐blockers have generally not been shown to be greater than for individual agents, possibly because overlapping mechanisms action. The authors tested additivity β‐blocker nebivolol, which has vasodilating activity, with angiotensin‐converting enzyme inhibitor lisinopril in patients stage 2 diastolic hypertension. BP...
Abstract OBJECTIVE Presenting a poor prognosis, gastric cancer (GC) remains one of the leading causes disease and death worldwide. N 7 -methylguanosine (m G) is most prevalent RNA modification. m G-long noncoding RNAs (lncRNAs) regulate GC onset progression, but their precise mechanism in unclear. MATERIALS AND METHODS The Cancer Genome Atlas database helped extract gene expression data clinical information for GC. Coexpression analysis identify G-related lncRNAs. Univariate Cox multivariate...
Objective: Case management-based interventions aimed at improving quality of care have the potential to narrow racial and ethnic disparities among people with chronic illnesses. The aim this study was assess equity effects assertive community treatment (ACT), an evidence-based case management intervention, homeless adults severe mental illness. Methods: This used baseline, three-, 12-month data for 6,829 black, Latino, white who received ACT services through ACCESS (Access Community Care...
For the success of a new drug development, it is crucial to select sensitive patient populations. To potentially reduce timeline and cost, we may apply two-stage adaptive population selection design therapeutic trial. In such design, based on early results trial, population(s) will be selected/determined for final stage analysis. Because this nature multiple between-treatment comparisons populations, an alpha adjustment necessary. article, propose closed step-down testing procedure assess...
329 Background: Tepotinib, a potent and highly selective MET inhibitor, showed promising activity in advanced HCC with overexpression two Phase Ib/II trials, which both met their primary endpoints. One trial enrolled Asian patients (pts) without prior systemic therapy (first line [1L]; NCT01988493) one US/European pts sorafenib (second [2L]; NCT02115373). By investigator assessment, objective response rates disease control tepotinib II were 15.8% 60.5% 1L (n = 38), 8.2% 57.1% 2L 49)....
Vascular remodeling caused by vascular injury such as hypertension and atherosclerosis is a complex process involving variety of cells factors, the mechanism unclear. A model was simulated adding norepinephrine (NE) to culture medium adventitial fibroblasts (AFs). NE induced activation proliferation AFs. To investigate association between AFs bone marrow mesenchymal stem (BMSCs) differentiation in remodeling. BMSCs were cultured with supernatant medium. BMSC migration observed immunostaining...
Objective: To investigate TLR2 and TLR4 expressional situation on the surface of peripheral blood mononuclear cells (PBMC) in patients with hepatocellular carcinoma (HCC) their relationship small intestinal bacterial overgrowth (SIBO). Methods: Flow cytometry was used to detect PBMC 78 cases HCC, 56 cirrhosis 33 healthy controls. Furthermore, lactose hydrogen breath test (LHBT) overgrowth. Results: Of (71.8%) were SIBO-positive, 23 (41.1%) SIBO- positive cirrhosis, 1 (3.0%) SIBO-positive The...
4087 Background: The incidence of hepatocellular carcinoma (HCC), a leading cause cancer death, is increasing with the chronic liver disease. Sorafenib, only approved systemic therapy for advanced HCC, provides modest improvement in overall survival. Preclinical studies suggest c-Met valid target but non-selective TKIs inhibitory activity have not shown efficacy trials, possibly due to lack inhibition. Tepotinib (MSC2156119J) highly selective inhibitor that has favorable safety and promising...
Alkaline Bi//Zn batteries with superb safety, low cost, and high power density are promising candidates for large-scale electrical energy storage. However, their developments severely limited by the Bi-based cathode as unsatisfying capacity cycle life. Herein, an innovative multistage cubic nanospheres Bi12 SiO20 (MCS-Bi12 ) is successfully synthesized a simple calcination method, which shows excellent storage performances of superior specific (294 mAh g-1 at 0.5 A outstanding rate...
Clinical study endpoints, including some biomarkers, are frequently analyzed after a log transformation. To calculate power for detecting between-treatment difference in the scale, an estimate of standard deviation log-transformed variable is needed. Often, though, only summary statistics original scale arithmetic means with corresponding deviations or sample medians and interquartile ranges found literature. In absence individual subjects' data directly calculating alternative approaches...